{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T13:59:43Z","timestamp":1792159183109,"version":"4.4.0"},"reference-count":23,"publisher":"Wiley","issue":"2S","license":[{"start":{"date-parts":[[2013,3,8]],"date-time":"2013-03-08T00:00:00Z","timestamp":1362700800000},"content-version":"vor","delay-in-days":5514,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[1998,2]]},"abstract":"<jats:p>Ketoprofen, a nonsteroidal anti\u2010inflammatory drug (NSAID) of the 2\u2010arylpropionic acid class, causes gastroduodenal hemorrhages and erosions in 10\u201315% of patients. The (S)\u2010 enantiomer exhibits most of the anti\u2010inflammatory properties, with concomitant gastrointestinal toxicity. The (R)\u2010 enantiomer, however, was recently found to have analgesic properties independent of prostaglandin inhibition. Seventy\u2010two healthy male volunteers not receiving NSAIDs, alcohol, or anti\u2010ulcer drugs, were enrolled in a randomized, investigator\u2010blind, placebo\u2010controlled trial to evaluate the gastroduodenal tolerance of (R)\u2010 ketoprofen 100 mg b.i.d., (R)\u2010 flurbiprofen 100 mg b.i.d., racemic ketoprofen 100 mg b.i.d., and paracetamol 1,000 mg b.i.d. Gastroduodenal endoscopies at baseline and after 2.5 days of dosing were used to detect newly occurring hemorrhages and erosions. Adverse events were also recorded. The incidence of submucosal hemorrhages was 4\/16 in the (R)\u2010 ketoprofen group, 5\/16 in the (R)\u2010 flurbiprofen group, 12\/16 in the racemic ketoprofen group, 1\/16 in the paracetamol group, and 1\/8 in the placebo group. The incidence of erosions was 2\/16 in the (R)\u2010 ketoprofen group, 4\/16 in the (R)\u2010 flurbiprofen group, 10\/16 in the racemic ketoprofen group, 0\/16 in the paracetamol group, and 2\/8 in the placebo group. The differences in hemorrhages and erosions among treatments were statistically significant (gastric hemorrhages P = 0.0008; duodenal hemorrhages P = 0.00062; gastric erosions P = 0.0004; duodenal erosions P = 0.0062, Kruskal\u2010Wallis test). At 100 mg b.i.d., (R)\u2010 ketoprofen caused fewer gastroduodenal hemorrhages and erosions than racemic ketoprofen (P = 0.019, P = 0.0112, P = 0.0097, P = 0.0139 for gastric, duodenal hemorrhages and gastric, duodenal erosions, respectively). The difference between 100 mg b.i.d. (R)\u2010 ketoprofen and 100 mg b.i.d (R)\u2010 flurbiprofen was not statistically significant. The dissociation between analgesic and anti\u2010inflammatory properties for (R)\u2010 ketoprofen suggests that it may represent a unique analgesic with a favorable safety profile. J Clin Pharmacol 1998;38:19S\u201024S.<\/jats:p>","DOI":"10.1002\/j.1552-4604.1998.tb04413.x","type":"journal-article","created":{"date-parts":[[2013,3,8]],"date-time":"2013-03-08T18:24:40Z","timestamp":1362767080000},"source":"Crossref","is-referenced-by-count":22,"title":["Clinical Endoscopic Evaluation of the Gastroduodenal Tolerance to (R)\u2010 Ketoprofen, (R)\u2010 Flurbiprofen, Racemic Ketoprofen, and Paracetamol: A Randomized, Single\u2010Blind, Placebo\u2010Controlled Trial"],"prefix":"10.1002","volume":"38","author":[{"given":"Thomas P.","family":"Jerussi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean\u2010Fran\u00e7ois","family":"Caubet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John E.","family":"McCray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean A.","family":"Handley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,3,8]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(96)90571-5"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199600525-00005"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1021\/js960276y"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600790522"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.3109\/03009749109097250"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.2165\/00044011-199509020-00005"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.2165\/00044011-199611060-00005"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.2165\/00044011-199611060-00002"},{"key":"e_1_2_1_10_2","first-page":"767","article-title":"Ethanol, aspirin, ibuprofen, and the gastroduodenal mucosa: an endoscopic assessment","volume":"80","author":"Lanza FL","year":"1985","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01540567"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1952.10483441"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.2307\/3001968"},{"key":"e_1_2_1_14_2","first-page":"21","article-title":"NSAID gastropathy in rheumatology: An audit and review of the literature","volume":"7","author":"Wright V","year":"1995","journal-title":"J Drug Dev Clin Pract"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01958153"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1992.tb04643.x"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/chir.530050703"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/35.suppl_1.61"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5107(95)70045-5"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1052-5157(18)30351-9"},{"key":"e_1_2_1_21_2","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1002\/j.1552-4604.1996.tb00003.x","article-title":"Pharmacodynamics and pharmacokinetics of the profens: Enantioselectivity, clinical implications, and special reference to S(+)\u2010ibuprofen","volume":"36","author":"Evans AM","year":"1996","journal-title":"J Clin Pharmacol"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1995.tb04537.x"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1159\/000201138"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.1994.tb00156.x"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fj.1552-4604.1998.tb04413.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/j.1552-4604.1998.tb04413.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T02:08:22Z","timestamp":1715047702000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/j.1552-4604.1998.tb04413.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,2]]},"references-count":23,"journal-issue":{"issue":"2S","published-print":{"date-parts":[[1998,2]]}},"alternative-id":["10.1002\/j.1552-4604.1998.tb04413.x"],"URL":"https:\/\/doi.org\/10.1002\/j.1552-4604.1998.tb04413.x","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[1998,2]]}}}